EpiSwitch® PSE Report

Personalized Immune Health 3D-Genetic Profile

Patient Name
Peterson, James

Date of Birth
22-DEC-1975

EpiSwitch PSE Profile

Your Result

Low Likelihood | High Likelihood

The **EpiSwitch Prostate Cancer Detection (PSE) Test** score indicates a **low likelihood of prostate cancer.** This result is consistent with the absence of cancer in more than 9 out of 10 men.

Your healthcare provider will consider this result along with other clinical features and history to determine an appropriate course of action, including active surveillance.

Patient Information

Gender	Male
Medical Record #	c14456d0
Report #	UKPSE-0254
Previous PSA test result (ng/mL)	3.0

Physician Release

Physician Name	Christopher Smith, MD
Facility Name	XXX-XXX-XXX-XXX
Address	[Number and Street Name] [Locality] [Town/City] [Postcode]
Phone	4210-811-555
Account Ref	NA

Specimen Information

Report Date	28-FEB-2023
Receipt Date	28-FEB-2023
Collection Date	20-FEB-2023
Specimen Type	WB EDTA K3
Specimen ID	D000097422

EpiSwitch Prostate Detection (PSE) Test Description

Intended Use: EpiSwitch Prostate Cancer Detection (PSE) Test is a blood-based test for prostate cancer that evaluates the PSA score plus a targeted PCR evaluation of five (5) DNA regulatory markers called chromatin-conformation signatures (CCS). The PSE test accurately predicts the presence or absence of prostate cancer; the significance, stage, and/or grade of the cancer will be determined from the biopsy. This information is valuable in determining who should proceed to biopsy and who can be placed on active surveillance without additional testing.

References

1. Pchejetski, D., et al. (2023). *Circulating Chromosome Conformation Signatures Significantly Enhance PSA Positive Predicting Value and Overall Accuracy for Prostate Cancer Detection*. Cancers, 15(3), 821. http://dx.doi.org/10.3390/cancers15030821
2. Alshaker, H., et al. (2021). *Chromatin conformation changes in peripheral blood can detect prostate cancer and stratify disease risk groups*. Journal of Translational Medicine, 19(1). https://doi.org/10.1186/s12967-021-02710-y

Disclaimer: The EpiSwitch Prostate Cancer Detection (PSE) Test is a laboratory developed test (LDT). The laboratory is accredited by UKAS to perform high-complexity clinical testing in compliance with ISO 15189. Decisions regarding patient care and treatment should not be solely based on a single test such as this test, rather, on the independent medical judgment of the treating physician taking into consideration all available information concerning the patient's conditions, including other clinical tests, in accordance with the standard of care in each healthcare setting.

The performance characteristics were established, and testing was performed at Oxford BioDynamics Pie, 3140 Rowan Place, John Smith Drive, Oxford Business Park South, Oxford, UK OX4 2WB.
For questions about the report, email PSE.TEST@myOBDX.com or call 01865 504932

These results were approved under authority delegated by Dr. Alexandre Akoulitchev, Medical Director

Date

EpiSwitch® PSE Report

Personalized Immune Health 3D-Genetic Profile

Patient Name
Peterson, James

Date of Birth
22-DEC-1975

EpiSwitch PSE Profile

Your Result

Low Likelihood | **High Likelihood**

The **EpiSwitch Prostate Cancer Detection (PSE) Test** result indicates a **high likelihood of prostate cancer.** This result is consistent with cancer being confirmed in more than 9 out of 10 men.

Your healthcare provider will consider this result along with other clinical features and history to determine which additional diagnostic test(s), such as a biopsy, is appropriate to confirm.

Patient Information

Gender	Male
Medical Record #	c14456d0
Report #	UKPSE-0254
Previous PSA test result (ng/mL)	3.0

Physician Release

Physician Name	Christopher Smith, MD
Facility Name	XXX-XXX-XXX-XXX
Address	[Number and Street Name] [Locality] [Town/City] [Postcode]
Phone	4210-811-555
Account Ref	NA

Specimen Information

Report Date	28-FEB-2023
Receipt Date	28-FEB-2023
Collection Date	20-FEB-2023
Specimen Type	WB EDTA K3
Specimen ID	D000097422

EpiSwitch Prostate Detection (PSE) Test Description

Intended Use: EpiSwitch Prostate Cancer Detection (PSE) Test is a blood-based test for prostate cancer that evaluates the PSA score plus a targeted PCR evaluation of five (5) DNA regulatory markers called chromatin-conformation signatures (CCS). The PSE test accurately predicts the presence or absence of prostate cancer; the significance, stage, and/or grade of the cancer will be determined from the biopsy. This information is valuable in determining who should proceed to biopsy and who can be placed on active surveillance without additional testing.

References

1. Pchejetski, D., et al. (2023). *Circulating Chromosome Conformation Signatures Significantly Enhance PSA Positive Predicting Value and Overall Accuracy for Prostate Cancer Detection.* Cancers, 15(3), 821. http://dx.doi.org/10.3390/cancers15030821
2. Alshaker, H., et al. (2021). *Chromatin conformation changes in peripheral blood can detect prostate cancer and stratify disease risk groups.* Journal of Translational Medicine, 19(1). https://doi.org/10.1186/s12967-021-02710-y

Disclaimer: The EpiSwitch Prostate Cancer Detection (PSE) Test is a laboratory developed test (LDT). The laboratory is accredited by UKAS to perform high-complexity clinical testing in compliance with ISO 15189. Decisions regarding patient care and treatment should not be solely based on a single test such as this test, rather, on the independent medical judgment of the treating physician taking into consideration all available information concerning the patient's conditions, including other clinical tests, in accordance with the standard of care in each healthcare setting.

The performance characteristics were established, and testing was performed at Oxford BioDynamics Pie, 3140 Rowan Place, John Smith Drive, Oxford Business Park South, Oxford, UK OX4 2WB.
For questions about the report, email PSE.TEST@myOBDX.com or call 01865 504932

These results were approved under authority delegated by Dr. Alexandre Akoulitchev, Medical Director

Date